Counting the cost of spinal muscular atrophy

Journal of Medical Economics

Volumn 19, Issue 8, 2016, Pages 827-828

  Gillingwater, Thomas H ^a,b  

^a Euan MacDonald Centre for Motor Neuron Disease Research   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; SURVIVAL MOTOR NEURON PROTEIN 1; SURVIVAL MOTOR NEURON PROTEIN;

CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; GENE THERAPY; GERMANY; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; NONHUMAN; NOTE; SPINAL MUSCULAR ATROPHY; ANIMAL; BIOSYNTHESIS; ECONOMICS; GENETICS; MUSCULAR ATROPHY, SPINAL; PATHOPHYSIOLOGY;

ANIMALS; HUMANS; MUSCULAR ATROPHY, SPINAL; SMN COMPLEX PROTEINS;

EID: 84976563297     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.1080/13696998.2016.1202833     Document Type: Note

References (18)

1. S.Lefebvre, L.Bürglen, S.Reboullet,. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995;80:155-65
2. A.H.Burghes, C.E.Beattie Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick? Nat Rev Neurosci 2009;10:597-609
3. G.Hamilton, T.H.Gillingwater Spinal muscular atrophy: going beyond the motor neuron. Trends Mol Med 2013;19:40-50
4. E.Mercuri, E.Bertini, S.T.Iannaccone Childhood spinal muscular atrophy: controversies and challenges. Lancet Neurol 2012;11:443-52
5. I.Faravelli, M.Nizzardo, G.P.Comi,. Spinal muscular atrophy–recent therapeutic advances for an old challenge. Nat Rev Neurol 2015;11:351-9
6. S.Tisdale, L.Pellizzoni Disease mechanisms and therapeutic approaches in spinal muscular atrophy. J Neurosci 2015;35:8691-700
7. M.Shababi, C.L.Lorson, S.S.Rudnik-Schöneborn Spinal muscular atrophy: a motor neuron disorder or a multi-organ disease? J Anat 2014;224:15-28
8. B.Wirth, M.Barkats, C.Martinat,. Moving towards treatments for spinal muscular atrophy: hopes and limits. Expert Opin Emerg Drugs 2015;20:353-6
9. A.L.Beaudet, L.Meng Gene-targeting pharmaceuticals for single-gene disorders. Hum Mol Genet 2016;25:R18-26
10. M.Ripolone, D.Ronchi, R.Violano,. Impaired muscle mitochondrial biogenesis and myogenesis in spinal muscular atrophy. JAMA Neurol 2015;72:666-75
11. M.Bowerman, A.Beauvais, C.L.Anderson,. Rho-kinase inactivation prolongs survival of an intermediate SMA mouse model. Hum Mol Genet 2010;19:1468-78
12. T.M.Wishart, C.A.Mutsaers, M.Riessland,. Dysregulation of ubiquitin homeostasis and β-catenin signaling promote spinal muscular atrophy. J Clin Invest 2014;124:1821-34
13. E.J.Groen, T.H.Gillingwater UBA1: at the crossroads of ubiquitin homeostasis and neurodegeneration. Trends Mol Med 2015;21:622-32
14. C.A.Chiriboga, K.J.Swoboda, B.T.Darras,. Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy. Neurology 2016;86:890-7
15. Y.Qian, S.McGraw, J.Henne,. Understanding the experiences and needs of individuals with Spinal Muscular Atrophy and their parents: a qualitative study. BMC Neurol 2015;15:217
16. S.E.Little, V.Janakiraman, A.Kaimal,. The cost-effectiveness of prenatal screening for spinal muscular atrophy. Am J Obstet Gynecol 2010;202:253 e1-7
17. E.P.Armstrong, D.C.Malone, W.S.Yeh,. The Economic Burden of Spinal Muscular Atrophy. J Med Econ 2016; doi: 10.1080/13696998.2016.1198355 [Epub ahead of print]
18. C.Klug, O.Schreiber-Katz, S.Thiele,. Disease burden of spinal muscular atrophy in Germany. Orphanet J Rare Dis 2016;11:58